Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are at least 18 years old at the time of signing the consent form
- People whose general health and ability to carry out daily activities meets a certain standard (rated 0 or 1 on a scale used by doctors to measure this)
- People who have a confirmed solid tumour — including but not limited to breast, ovarian, pancreatic, endometrial, or liver cancer — that has spread or cannot be removed by surgery, and for whom standard treatments no longer exist or are no longer working
- People whose cancer can be measured using standard imaging criteria (confirm with trial site)
- People whose blood counts and organ function meet minimum required levels
- People with a life expectancy of more than 3 months
Who may not be able to join:
- People who have received systemic anti-cancer treatment within 4 weeks before the first dose of the study drug
- People who have had major surgery within 4 weeks before the first dose of the study drug
- People who have other serious illnesses that are not under control
- People with a known history of a rare inherited condition affecting how the body processes fats, such as Wolman disease or Cholesterol Ester Storage Disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rasha Cosman, MBBS, The Kinghorn Cancer Centre
Phone: 01 469 600 6603
Australian sites
+61 (2) 9812 3000
(02) 8890 6666
08 8359 2565
08 8474 0220
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence of Dose Limiting Toxicities of ERX-315; Incidence of Adverse Events as a measure of safety and tolerability of ERX-315; Incidence of laboratory abnormalities as a measure of safety and tolerability of ERX-315; Determination of the recommended phase 2 dose
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.